We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+15.22%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$280M
AUM Growth
+$4.87M
Cap. Flow
-$17.4M
Cap. Flow %
-6.19%
Top 10 Hldgs %
28.7%
Holding
166
New
40
Increased
28
Reduced
35
Closed
35

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$5.21M
2
ANSS
Ansys
ANSS
+$4.33M
3
JNPR
Juniper Networks
JNPR
+$4.19M
4
GDX icon
VanEck Gold Miners ETF
GDX
+$2.49M
5
SWTX
SpringWorks Therapeutics
SWTX
+$2.36M

Top Sells

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$12.3M
2
IMVT icon
Immunovant
IMVT
+$5.11M
3
IMGN
Immunogen Inc
IMGN
+$4.29M
4
SPLK
Splunk Inc
SPLK
+$4.2M
5
SOVO
Sovos Brands, Inc. Common Stock
SOVO
+$4.07M

Sector Composition

Rank Sector Weight
1 Healthcare 44.78%
2 Technology 11.84%
3 Consumer Discretionary 7.8%
4 Industrials 6.17%
5 Financials 4.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLB icon
151
SLB Ltd
SLB
$79.7B
– –
-26,700
Closed -$1.39M
TECK icon
152
Teck Resources
TECK
$32.4B
– –
-34,562
Closed -$1.46M
TEVA icon
153
Teva Pharmaceuticals
TEVA
$42.5B
– –
-124,700
Closed -$1.3M
TRU icon
154
TransUnion
TRU
$15.4B
– –
-19,400
Closed -$1.33M
UDMY
155
DELISTED
Udemy
UDMY
– –
-18,497
Closed -$272K
UTHR icon
156
United Therapeutics
UTHR
$22.1B
– –
-2,299
Closed -$506K
WST icon
157
West Pharmaceutical
WST
$24.7B
– –
-2,900
Closed -$1.02M
X
158
DELISTED
US Steel
X
– –
-35,400
Closed -$1.72M
TXNM
159
TXNM Energy Inc
TXNM
$5.91B
– –
-69,909
Closed -$2.91M
EXE
160
Expand Energy Corp
EXE
$22.7B
– –
-15,016
Closed -$1.16M
SGI
161
Somnigroup International
SGI
$13.7B
– –
-34,000
Closed -$1.73M
CBAY
162
DELISTED
Cymabay Therapeutics
CBAY
– –
-160,334
Closed -$3.79M
SPLK
163
DELISTED
Splunk Inc
SPLK
– –
-27,600
Closed -$4.2M
SOVO
164
DELISTED
Sovos Brands, Inc. Common Stock
SOVO
– –
-184,600
Closed -$4.07M
AMAM
165
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-203,122
Closed -$2.89M
IMGN
166
DELISTED
Immunogen Inc
IMGN
– –
-144,772
Closed -$4.29M
3 4 5 6
7

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q1 2024 Portfolio in Review

As of Q1 2024, HighVista Strategies held 166 positions worth $280M, up 1.8% from $276M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies withdrew a net $17.4M in Q1 2024, closing 35 positions and reducing 35 holdings. Its most notable exit was Immunovant, an estimated $5.11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 46% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, HighVista Strategies opened a new position in Apogee Therapeutics worth $7.93M.

  • HighVista Strategies's largest Q1 2024 buy was Apogee Therapeutics: 119,403 shares worth $7.93M.
  • HighVista Strategies added most to argenx in Q1 2024, an estimated $2.2M increase.
  • HighVista Strategies's biggest Q1 2024 reduction was Spyre Therapeutics, cutting an estimated $12.3M.
  • HighVista Strategies fully exited Immunovant in Q1 2024, selling an estimated $5.11M.
  • HighVista Strategies's ten largest holdings make up 29% of its $280M portfolio in Q1 2024.
  • HighVista Strategies opened 40 new positions and closed 35 in Q1 2024.
  • HighVista Strategies's portfolio value rose 1.8% quarter-over-quarter to $280M.

Based on HighVista Strategies's 13F filing for Q1 2024, filed 15 May 2024.